Status:
COMPLETED
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Lead Sponsor:
Mirati Therapeutics Inc.
Conditions:
Advanced Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and ...
Detailed Description
During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed. During the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients...
Eligibility Criteria
Inclusion
- Metastatic or unresectable solid tumor malignancy
- Standard treatment is not available
- Adequate bone marrow and organ function
Exclusion
- History of a significant cardiovascular illness
- Prolonged corrected QT (QTc) interval
- Left ventricular ejection fraction \< 40%
- Symptomatic or uncontrolled brain metastases
- Other active cancer
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 27 2022
Estimated Enrollment :
193 Patients enrolled
Trial Details
Trial ID
NCT02219711
Start Date
August 1 2014
End Date
April 27 2022
Last Update
March 6 2023
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35294
2
University of California, San Diego
San Diego, California, United States, 92093
3
University of California, San Francisco
San Francisco, California, United States, 94143
4
Sarcoma Oncology Research Center
Santa Monica, California, United States, 90403